Green tea is already quite a rage in the health sector and has actually benefited people in reducing weight and solving other health issues. Now according to this new study, green tea is also effective in reducing the kidney toxicity and damage caused by cisplatin — an anti-cancer drug, the AIIMS researchers have revealed. The research study has evaluated the usefulness of ECG, a polyphenolic compound obtained from green tea in preventing the damage of kidneys induced by the cisplatin. Side effects of cisplatin may include nephrotoxicity and life-threatening damaged kidney.
The study by AIIMS Professor Jagriti Bhatia from the Pharmacology Department was published in journal ‘Laboratory Investigations’ recently. “If this research progresses, it may lead to a new drug which can combat the ill effects of cisplatin,” said Bhatia.
Approximately 30 per cent of the treated patients may develop nephrotoxicity after receiving an initial dose of cisplatin. Cisplatin causes production of free radicals inside cells in kidney which leads to oxidative stress and inflammation.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022